Wells Fargo
DNA icon

Wells Fargo’s Ginkgo Bioworks DNA Stock Holding History

Wells Fargo’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$415K Buy
41,908
+20,299
+94% +$170K ﹤0.01% 4754
2026
Q1 		$132K Sell
21,609
-30,526
-59% -$254K ﹤0.01% 4943
2025
Q4 		$433K Buy
52,135
+20,235
+63% +$218K ﹤0.01% 4595
2025
Q3 		$465K Buy
31,900
+4,544
+17% +$54.4K ﹤0.01% 4355
2025
Q2 		$308K Buy
27,356
+25,112
+1,119% +$195K ﹤0.01% 4483
2025
Q1 		$12.8K Buy
2,244
+1,852
+472% +$18.9K ﹤0.01% 5833
2024
Q4 		$3.85K Sell
392
-244
-38% -$2.09K ﹤0.01% 6104
2024
Q3 		$5.18K Sell
636
-638
-50% -$6.39K ﹤0.01% 5909
2024
Q2 		$17K Sell
1,274
-775
-38% -$23.1K ﹤0.01% 5624
2024
Q1 		$95.1K Buy
2,049
+163
+9% +$8.44K ﹤0.01% 4922
2023
Q4 		$127K Sell
1,886
-434
-19% -$26.6K ﹤0.01% 4757
2023
Q3 		$168K Buy
2,320
+151
+7% +$12.1K ﹤0.01% 4473
2023
Q2 		$161K Buy
2,169
+599
+38% +$35.5K ﹤0.01% 4720
2023
Q1 		$83.5K Buy
1,570
+358
+30% +$22.7K ﹤0.01% 4898
2022
Q4 		$82K Sell
1,212
-95
-7% -$8.74K ﹤0.01% 4634
2022
Q3 		$163K Buy
1,307
+178
+16% +$21.2K ﹤0.01% 4348
2022
Q2 		$107K Buy
1,129
+298
+36% +$36.3K ﹤0.01% 4599
2022
Q1 		$135K Sell
831
-4,037
-83% -$786K ﹤0.01% 5183
2021
Q4 		$1.62M Buy
4,868
+4,323
+793% +$2.05M ﹤0.01% 3700
2021
Q3 		$252K Buy
+545
New +$265K ﹤0.01% 5005

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Wells Fargo's DNA Position: Q2 2026 in Review

Wells Fargo increased its Ginkgo Bioworks (DNA) stake by 94% in Q2 2026, buying an estimated $170K and bringing the position to 41,908 shares worth $415K. The position accounts for ﹤0.01% of the portfolio, ranked #4754.

Wells Fargo first reported a position in DNA in Q3 2021 and has held it in 20 quarters since. The position peaked at $1.62M in Q4 2021. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Wells Fargo held 41,908 shares of Ginkgo Bioworks worth $415K as of Q2 2026.
  • Wells Fargo bought 20,299 Ginkgo Bioworks shares in Q2 2026, an estimated $170K.
  • Ginkgo Bioworks made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4754 holding.
  • Wells Fargo first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 20 quarters since.
  • Wells Fargo's Ginkgo Bioworks position peaked at $1.62M in Q4 2021.
  • 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.